Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Jahn

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|November 12, 2020
Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in MalawiYuli L Hsieh, Andreas Jahn, Nicolas A Menzies, et al.
Lancet (London, England)|July 19, 2011
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approachErik J Schouten, Andreas Jahn, Dalitso Midiani, et al.
The Lancet. HIV|August 16, 2023
Trends in HIV prevalence, incidence, and progress towards the UNAIDS 95-95-95 targets in Malawi among individuals aged 15-64 years: population-based HIV impact assessments, 2015-16 and 2020-21Danielle Payne, Nellie Wadonda-Kabondo, Alice Wang, et al.
The Lancet. Global Health|September 20, 2024
Assessing the effect of health system resources on HIV and tuberculosis programmes in Malawi: a modelling studyTara D Mangal, Sakshi Mohan, Timothy Colbourn, et al.
Human Mutation|July 11, 2012
Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunitiesFlorian Mittag, Finja Büchel, Mohamad Saad, et al.
Antiviral Therapy|August 17, 2022
Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in MalawiGeorge Bello, Matthew Kagoli, Sikhona Chipeta, et al.
Plos One|October 27, 2025
"I just thought I was lucky to be protected from HIV:" Qualitative evaluation of barriers and facilitators of pre-exposure prophylaxis use for adolescent girls and young women at higher risk of HIV acquisition in Lilongwe, MalawiMallory Michalak, Odala Sande, Sam Phiri, et al.
The Lancet. HIV|December 4, 2018
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyAndrew N Phillips, Francois Venter, Diane Havlir, et al.
Plos Medicine|February 15, 2020
Emerging priorities for HIV service deliveryNathan Ford, Elvin Geng, Tom Ellman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2012
Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment programNellie Wadonda-Kabondo, Diane Bennett, Joep J van Oosterhout, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|November 12, 2020
Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in MalawiYuli L Hsieh, Andreas Jahn, Nicolas A Menzies, et al.
Lancet (London, England)|July 19, 2011
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approachErik J Schouten, Andreas Jahn, Dalitso Midiani, et al.
The Lancet. HIV|August 16, 2023
Trends in HIV prevalence, incidence, and progress towards the UNAIDS 95-95-95 targets in Malawi among individuals aged 15-64 years: population-based HIV impact assessments, 2015-16 and 2020-21Danielle Payne, Nellie Wadonda-Kabondo, Alice Wang, et al.
The Lancet. Global Health|September 20, 2024
Assessing the effect of health system resources on HIV and tuberculosis programmes in Malawi: a modelling studyTara D Mangal, Sakshi Mohan, Timothy Colbourn, et al.
Human Mutation|July 11, 2012
Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunitiesFlorian Mittag, Finja Büchel, Mohamad Saad, et al.
Antiviral Therapy|August 17, 2022
Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in MalawiGeorge Bello, Matthew Kagoli, Sikhona Chipeta, et al.
Plos One|October 27, 2025
"I just thought I was lucky to be protected from HIV:" Qualitative evaluation of barriers and facilitators of pre-exposure prophylaxis use for adolescent girls and young women at higher risk of HIV acquisition in Lilongwe, MalawiMallory Michalak, Odala Sande, Sam Phiri, et al.
The Lancet. HIV|December 4, 2018
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyAndrew N Phillips, Francois Venter, Diane Havlir, et al.
Plos Medicine|February 15, 2020
Emerging priorities for HIV service deliveryNathan Ford, Elvin Geng, Tom Ellman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2012
Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment programNellie Wadonda-Kabondo, Diane Bennett, Joep J van Oosterhout, et al.
Pageof 16